Business Wire

The Estée Lauder Companies Announces Appointment of Mark Loomis to Lead North America

19.11.2021 02:38:00 EET | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Mark Loomis, currently President, Asia/Pacific, will be appointed President, North America, effective February 1, 2022. Mark will report directly to Fabrizio Freda, President and Chief Executive Officer, and he will remain a member of ELC’s Executive Leadership Team. An announcement regarding Asia/Pacific leadership will follow.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006408/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ELC Appoints Mark Loomis as President, North America (Photo: Business Wire)

“We are thrilled that Mark will take on leadership of our home market in North America,” said Fabrizio Freda, President and Chief Executive Officer. “Mark has successfully built and led high-performance organizations throughout his 25 years at The Estée Lauder Companies, delivering incredible results through his visionary strategic leadership and collaborative style. I look forward to our continued close partnership as Mark leads our talented North America team to build on their successes as the region continues to gain momentum.”

As President, North America, Mark’s responsibilities will include guiding the North America Leadership Team to help maximize sales, profitability, and market share growth in the company’s dynamic and fast-evolving home market. He will build on the region’s many successes, leveraging his commercial expertise to help drive the business strategy, fuel the recovery, and unlock opportunities across brands, consumers, and channels.

Mark will have accountability for top- and bottom-line results in the U.S. and Canada across brands and channels. Working closely with the North America Leadership Team, he will drive ELC’s continued transformation as a digital-first organization fueled by Online. He will leverage the company’s strong retailer relationships to help optimize productivity and create exceptional omni-experiences for consumers.

Mark will partner closely with ELC’s Group and Brand Presidents and Function leaders on innovation pipeline sufficiency, elevated brand equity-building, and resource allocation to the largest growth opportunities. He will nurture the region’s organizational culture to enable brands to execute their strategies with the greatest support, focus, speed, and agility, while also driving greater integration and best practices across the portfolio.

Mark has had an exemplary 25-year career with ELC, much of it spent in Asia, with deep global leadership experience spanning the company’s brands, channels, regions, and affiliates. In these roles, he has delivered exceptional results, successfully leading strategically significant beauty markets, including ELC’s businesses in Canada and Japan.

As President, Asia/Pacific, since 2018, Mark has led the region to extraordinary new heights through regional strategies that support business acceleration and commercial operations to drive growth across all 13 Asia/Pacific affiliates. His tenacity in identifying and driving key business opportunities helped to grow net sales for Asia/Pacific significantly and double the region’s Online business between fiscal 2019 and 2021.

Mark was instrumental to the company’s multi-year transformation initiative focused on elevating and growing the company’s business in the Asia/Pacific region and winning with the Chinese consumer domestically and abroad. He has partnered closely with Joy Fan, newly appointed President and CEO, China, as well as the Travel Retail team, in one of the most competitive and dynamic prestige beauty markets in the world. He has also been central to the development of enterprise-wide initiatives to serve consumers with speed, innovation, and local-relevance, including the company’s investment in the first-ever manufacturing facility in Japan, the expansion of ELC’s innovation capabilities through its new China Innovation Center in Shanghai, as well as the acquisition of Dr.Jart+ and Do The Right Thing in 2019.

“Throughout his tenure, Mark has demonstrated an unwavering commitment to business success, while also commanding the deep respect of everyone with whom he engages and cultivating a strong sense of ambition, belonging, and pride across the company,” said William P. Lauder, Executive Chairman. “Mark’s inspiring leadership abilities, strong strategic vision, and focus on business performance and results are matched only by his commitment to our teams, making him well suited to take on this role at the helm of ELC’s home market in North America.”

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may address our expectations regarding sales, earnings or other future financial performance and liquidity, other performance measures, product introductions, entry into new geographic regions, information technology initiatives, new methods of sale, our long-term strategy, restructuring and other charges and resulting cost savings, and future operations or operating results. Factors that could cause actual results to differ materially from our forward-looking statements are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2021. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye